<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215266</url>
  </required_header>
  <id_info>
    <org_study_id>AB 31/05 RUTT 204</org_study_id>
    <secondary_id>2005-006098-29</secondary_id>
    <nct_id>NCT01215266</nct_id>
  </id_info>
  <brief_title>Sorafenib in Urothelium Cancer of Bladder</brief_title>
  <official_title>Prospektiv, Randomisierte, Doppelblinde, Multizentrische Phase-II- Studie Zum Vergleich Der Wirksamkeit Einer Chemotherapie Mit Gemcitabin Plus Cisplatin Und Sorafenib (BAY 43-9006) Versus Gemcitabin Plus Cisplatin Und Plazebo in Der Therapie Des Lokal Fortgeschrittenen Bzw. Metastasierten Urothelkarzinoms AB 31/05 - RUTT 204 - SUSE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association of Urologic Oncology (AUO)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Association of Urologic Oncology (AUO)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the use of Sorafenib additionally to gemcitabine and&#xD;
      cisplatin in bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A controlled, double-blind, randomized study to evaluate the influence of Sorafenib in&#xD;
      bladder cancer patients additionally to chemotherapy with gemcitabine and cisplatin compared&#xD;
      to placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment&#xD;
  </why_stopped>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rates, time of response</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation and comparison in both treatment arms</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Day 3-21 2x2 800 mg(milligram) daily</description>
    <arm_group_label>Sorafenib</arm_group_label>
    <other_name>Prüfsubstanz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Day 3-21 2x2 800 mg(milligram) daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Plazebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Men and Women &gt; 18 years&#xD;
&#xD;
          -  Condition ECOG(Eastern Cooperative Oncology Group) 0-1&#xD;
&#xD;
          -  Life expectancy at least 12 weeks&#xD;
&#xD;
          -  Women in conceptional age: negative pregnancy test and adequate contraception (oral&#xD;
             contraceptive, spiral); at men adequate contraception of the man (condom use) to 3&#xD;
             months after discontinuation of therapy with sorafenib&#xD;
&#xD;
          -  Histologically or cytologically proven urothelial carcinoma of the bladder or upper&#xD;
             urinary tract&#xD;
&#xD;
          -  Locally advanced or metastatic urothelial carcinoma of the bladder or upper urinary&#xD;
             tract (T3b,T4/ N+/M+)&#xD;
&#xD;
          -  At least one unidimensional measurable lesion on CT(Computed Tomography) or&#xD;
             MRI(Magnetic resonance imaging) according to RECIST(Response Evaluation Criteria in&#xD;
             Solid Tumors) criteria&#xD;
&#xD;
          -  Adequate hematologic, renal, hepatic and coagulation-physiological functions&#xD;
&#xD;
          -  Leukocytes &gt; 1.500 cells /ml (per milliliter)&#xD;
&#xD;
          -  Hemoglobin &gt;9g/dl(gram per deciliter)&#xD;
&#xD;
          -  Platelet &gt; 100000 /ml&#xD;
&#xD;
          -  Serum creatinine &lt; 2 x upper limit of normal or creatinine clearance ≥ 45 ml/min&#xD;
             (milliliter per minute)&#xD;
&#xD;
          -  Total Bilirubin &lt; 1,5 x upper limit of normal&#xD;
&#xD;
          -  GOT/GPT (glutamate-oxalacetate-transaminase/glutamate-pyruvate-transaminase) &lt; 2,5 x&#xD;
             upper limit of normal, at liver metastases &lt; 5x upper limit of normal&#xD;
&#xD;
          -  alkaline phosphates &lt; 5 x upper limit of normal&#xD;
&#xD;
          -  Amylase/ Lipase &lt; 1,5 x upper limit of normal&#xD;
&#xD;
          -  INR(International Normalized Ratio) und PTT(Partial Thromboplastin Time) &lt; 1,5 x upper&#xD;
             limit of normal&#xD;
&#xD;
          -  Informing the patient about the study and the present written consent to participate&#xD;
             after clarification in accordance with the stipulations of AMG(german drug law), and&#xD;
             the principles of the Ethics Committee (&quot;informed consent&quot;).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absence of the above inclusion criteria&#xD;
&#xD;
          -  Dialysis after nephrectomy&#xD;
&#xD;
          -  Patients with brain tumors and / or brain metastases&#xD;
&#xD;
          -  Previous or existing serious cardiovascular (grade III - IV according to NYHA(New York&#xD;
             Heart Association)) disease, active angina pectoris or ischemia, myocardial infarction&#xD;
             within 6 months prior to enrollment, or patients with serious cardiac arrhythmias&#xD;
             requiring antiarrhythmic therapy (beta blockers and digoxin are permitted)&#xD;
&#xD;
          -  Patients with uncontrolled high blood pressure, systolic blood pressure&gt; 150 mm Hg or&#xD;
             diastolic pressure&gt; 90 mmHg despite optimal medical treatment&#xD;
&#xD;
          -  Patients with thrombotic or embolic events such as stroke or pulmonary embolism&#xD;
&#xD;
          -  Patients with recently or known bleeding diathesis&#xD;
&#xD;
          -  Known significant neurological or psychiatric diseases including dementia and&#xD;
             epileptic seizures&#xD;
&#xD;
          -  Serious inflammatory eye disease, hearing impairment&#xD;
&#xD;
          -  Pulmonary (pO2(Blood oxygen) &lt;60 mm Hg(Millimeters of mercury)), hematopoietic&#xD;
             (eg(exempli gratia) severe bone marrow aplasia), hepatic or renal disease&#xD;
&#xD;
          -  Patients with poorly controlled diabetes mellitus&#xD;
&#xD;
          -  Serious bacterial or fungal infections(&gt;Grade 2 NCI-CTC(National Cancer&#xD;
             Institute-Common Terminology Criteria) Version 3)&#xD;
&#xD;
          -  chronic hepatitis B or C, HIV(human immunodeficiency virus) infection&#xD;
&#xD;
          -  Autoimmune disease&#xD;
&#xD;
          -  Allergic reactions to be used in respect of a drug&#xD;
&#xD;
          -  prior organ transplantation&#xD;
&#xD;
          -  prior autologous bone marrow transplant or stem cell transferred within the last 4&#xD;
             months before study&#xD;
&#xD;
          -  Manifesto, second malignancy or other malignancy within the past 5 years (except basal&#xD;
             cell carcinoma, carcinoma in situ of the cervix, incidental prostate carcinoma)&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Lack of cooperation and the ability to cooperate, predictable problems with the&#xD;
             aftercare, psychiatric disorders, substance abuse, lack of capacity of the patient&#xD;
&#xD;
          -  Participation in other treatment studies in the last 4 weeks&#xD;
&#xD;
          -  Previous treatment with chemotherapy or immunotherapy&#xD;
&#xD;
          -  Simultaneous treatment with other anti-tumor therapies after study start&#xD;
&#xD;
          -  Intravesical chemotherapy within the last 4 weeks&#xD;
&#xD;
          -  Irradiation within the last 4 weeks&#xD;
&#xD;
          -  Previous radiation therapy, when all were irradiated to the assessment of tumor&#xD;
             response used lesions&#xD;
&#xD;
          -  Complex operations, open biopsy or significant injuries within the last 4 weeks before&#xD;
             study&#xD;
&#xD;
          -  Serious wound healing disorder, ulcers or bone fractures in the last 4 weeks before&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne Krege, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Universität Duisburg-Essen</affiliation>
  </overall_official>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>October 1, 2010</study_first_submitted>
  <study_first_submitted_qc>October 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2010</study_first_posted>
  <last_update_submitted>September 7, 2011</last_update_submitted>
  <last_update_submitted_qc>September 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bladder cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Urothelium cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

